In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an HTA (health technology assessment) could reduce drug costs and improve health outcomes in the US. The group considers the benefits offered by NICE (The National Institute for Health and Care Excellence) and ICER (the Institute for Clinical and Economic Review). The authors provide six recommendations relating to the scope of such an organization.
The authors note, “The dimensions of value most often include clinical effectiveness, safety, costs and economic implications and may include ethical, social, cultural and legal issues, organizational and environmental aspects, as well as wider implications for the patient, relatives, caregivers and population. The overall value may vary depending on the perspective taken, the stakeholders involved and the decision context.” Read more here.
(Source: USC Health Policy, 2021)